Last week, Tada Group's Chief Operating Officer, Rebecca Stjernberg Bejhed, visited the Test och innovation center at Universitetssjukhuset i Linköping, Region Östergötland. The purpose of the visit was to conduct usability testing for the ReLink device, focusing on a new medical indication. This session provided an invaluable opportunity to gather feedback from experienced nurses and to observe how they integrated ReLink into their workflow.
The nurses’ insights were instrumental, offering both commendations and constructive criticism on the device's functionality. Engaging with healthcare professionals who candidly shared their thoughts, whether positive or negative, proved highly efficient in refining our approach and understanding future needs.
Rebecca Stjernberg Bejhed expressed her appreciation for the hands-on experience and the direct feedback received during the testing. She noted that such interactions are crucial for ensuring that ReLink not only meets but exceeds the standards expected in clinical settings.
The session highlighted important considerations for the new indication, paving the way for further development and optimization of the ReLink device. The feedback will inform our future design and implementation strategies, ensuring that ReLink continues to advance patient safety and improve healthcare outcomes.
Tada Group extends its gratitude to Test och innovation for facilitating this significant opportunity and to Elisabeth Willén for ensuring the day’s success. This collaboration marks another step forward in our mission to innovate and enhance the field of IV therapy.
Comments